RWM
IBRX icon

Rialto Wealth Management’s ImmunityBio IBRX Stock Holding History

Rialto Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438 Hold
50
– – ﹤0.01% 1769
2026
Q1 		$384 Hold
50
– – ﹤0.01% 1482
2025
Q4 		$99 Buy
50
+46
+1,150% +$104 ﹤0.01% 1635
2025
Q3 		$10 Hold
4
– – ﹤0.01% 1704
2025
Q2 		$11 Buy
+4
New +$11 ﹤0.01% 1699

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rialto Wealth Management's IBRX Position: Q2 2026 in Review

Rialto Wealth Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 50 shares worth $438. The position accounts for ﹤0.01% of the portfolio, ranked #1769.

Rialto Wealth Management first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Rialto Wealth Management held 50 shares of ImmunityBio worth $438 as of Q2 2026.
  • Rialto Wealth Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1769 holding.
  • Rialto Wealth Management first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.